NASDAQ · CINGW
Healthcare · Biotechnology
$0.01
Up+$0.00 (+0.00%)
Updated Oct 11, 2026, 5:26 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CINGW
1M range · 10 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
CINGW closed at $0.01 after 10 trading sessions, down 14.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.0035 | $0.0065 | $0.0035 | $0.0065 | 159.65K |
| Oct 5, 2026 | $0.0051 | $0.0051 | $0.003 | $0.0035 | 54.53K |
| Oct 2, 2026 | $0.0051 | $0.0051 | $0.0051 | $0.0051 | 100 |
| Sep 30, 2026 | $0.0081 | $0.0091 | $0.0051 | $0.0051 | 5.64K |
| Sep 29, 2026 | $0.007 | $0.007 | $0.006 | $0.0062 | 669 |
| Sep 28, 2026 | $0.006 | $0.006 | $0.006 | $0.006 | 2.01K |
| Sep 23, 2026 | $0.006 | $0.007 | $0.006 | $0.006 | 20.13K |
| Sep 21, 2026 | $0.0067 | $0.0067 | $0.0067 | $0.0067 | 10.14K |
| Sep 18, 2026 | $0.0061 | $0.0062 | $0.0061 | $0.0061 | 1.87K |
| Sep 15, 2026 | $0.0076 | $0.0076 | $0.0076 | $0.0076 | 1.64K |
The latest Smart Investors Daily articles mentioning CINGW.
Company
Market Activity
Research & News
CINGW research
Company profile and research snapshot.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 15, 2025
Cingulate Inc. placed CEO Shane J. Schaffer on administrative leave due to unrelated legal matters. Jennifer Callahan was appointed interim CEO, retaining her CFO role, while board member Jay Roberts became Executive Chairman to ensure business continuity.
GlobeNewswire Inc. · Mar 26, 2025
Cingulate Inc. reported positive results for its lead ADHD asset CTx-1301, including successful completion of Phase 3 trials and plans to submit a New Drug Application in mid-2025. The company also strengthened its balance sheet through various financing activities.
GlobeNewswire Inc. · Aug 23, 2024
Cingulate Inc. has adjourned its Special Meeting of Stockholders to provide additional time for stockholders to vote on all proposals. The company's Board of Directors continues to believe that the proposals are in the best interests of the stockholders.
GlobeNewswire Inc. · Aug 15, 2024
Cingulate Inc. announced that it was issued a European patent for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The patent will cover up to 30 European territories, including the United Kingdom.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CINGW.
No results
No recent SID articles mention CINGW.
